Recurrent Astrocytoma, IDH-Mutant, Grade 4 Clinical Trials

5 clinical trials for Recurrent Astrocytoma, IDH-Mutant, Grade 4 across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma — RECRUITING · PHASE1
• Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas — RECRUITING · PHASE1
• Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma — RECRUITING · PHASE1
• GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma — RECRUITING · PHASE2
• Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy — RECRUITING · PHASE1

Refine this search